Randomized comparison of ceftriaxone versus ceftriaxone plus amikacin for the empirical treatment of infections in patients with altered host defense: microbiological and clinical evaluation.
Two hundred and eighty-four febrile episodes in immunocompromised patients were treated with ceftriaxone alone or in combination with amikacin. In the ceftriaxone-treated group, 60 out of 143 febrile episodes were microbiologically documented, while in the group receiving the combination therapy, there were 32 out of 140 (p = 0.0007). Gram-positive microorganisms were more common than gram-negative ones, accounting for 59 of the 101 isolated bacteria. The ceftriaxone regimen appeared to have a response rate comparable to the combination regimen (73.91 vs. 78.88%). Superinfections occurred under both regimens.
D'Antonio
D
D
Laboratorio di Microbiologia Clinica, Ospedale Civile, Pescara, Italia.
Fioritoni
G
G
Iacone
A
A
Dell'Isola
M
M
Natale
D
D
D'Arcangelo
L
L
Betti
S
S
Spadano
A
A
Recchia
A
A
Mastrangelo
C
C
D000328:Adult; D000583:Amikacin / Q000627:therapeutic use; D001424:Bacterial Infections / Q000188:drug therapy* / Q000276:immunology; D002443:Ceftriaxone / Q000627:therapeutic use*; D004359:Drug Therapy, Combination / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D008297:Male
D002443:Ceftriaxone; D000583:Amikacin